| Literature DB >> 35099715 |
Michael Cimorelli1, Michael A Flynn2, Brett Angel3,4, Emily Reimold5, Sahil S Banka6, Benjamin Andrien2, Aaron Fafarman2, Richard Huneke5, Andrew Kohut7, Steven Wrenn1,8.
Abstract
Ultrasound enhancing agents are approved to delineate the endocardial border and opacify the left ventricle cavity (LVC). We present a nested phase change agent (NPCA) designed to enable selective myocardial enhancement without enhancing the LVC by employing a dual-activation mechanism dependent on sufficient ultrasound intensity and the microenvironment of the myocardium. Swine received bolus injections of NPCA while echocardiograms were collected and processed to determine background-subtracted acoustic intensities (AI) in the LVC and septal myocardium. At mechanical index (MI) ≥ 0.8, the NPCA enhanced the myocardium selectively (p < 0.001) while the LVC remained at baseline AI. A 5-mL bolus of NPCA enhanced swine myocardium and enhancement persisted for > 5 min at 1.4 MI, while hemodynamics and EKG remained normal. Our findings demonstrate that the NPCA enhances swine myocardium selectively without enhancing the LVC. The NPCA could have utility for functional and structural echocardiographic studies with clinical ultrasound using standard settings.Entities:
Keywords: Myocardial contrast echocardiography; Myocardial perfusion imaging; Nested phase change agent; Selective myocardial enhancement; Ultrasound enhancing agent
Year: 2022 PMID: 35099715 PMCID: PMC9339037 DOI: 10.1007/s12265-022-10207-2
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN: 1937-5387 Impact factor: 3.216